STEMBIOSYS
OperatingStemBioSys, Inc.
Healthcare · Technology · San Antonio, TX · Founded 2012
The next evolution in cell culture
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
10 people
Robert Hutchens, MBA, brings 20+ years of consulting experience from Booz & Co. (now Strategy&) & A.T. Kearney, focusing on Life Sciences. He worked on the CDC's $4B VFC program & collaborated with PEPFAR and the Global Fund. Bob joined StemBioSys as President & CEO in 2014, after investing in 2013.
Steven A. Davis, M.D., co-founded StemBioSys® in 2010. As a dermatologist and adjunct professor at UT Health San Antonio, he has conducted 200+ clinical trials for major companies. With a B.A. from Yale and an M.D. from UT Southwestern, he's active in San Antonio's biomedical community and serves on StemBioSys®'s board.
Mark Horsey, MBA, assisted in startups like Rapamycin Holdings, Bluegrass Vascular, and others with business and financial support. Formerly with Genzyme and Dell, he holds a BA in Economics and an MBA from St. Edwards University in Austin. Named CFO in 2013, he currently works 30 hours weekly at StemBioSys.
Xiao-Dong Chen, M.D., Ph.D., a pioneer in stem cell research, co-founded StemBioSys® based on patented work at UT Health San Antonio. He serves as the company's CSO with extensive experience and over 70 peer-reviewed articles. Dr. Chen has been on the board since inception, holding a Ph.D. in developmental immunology and hematology.
Fred brings 30+ years of medtech experience, from engineering to executive roles. He's led companies like Aerin Medical & ENTrigue Surgical, with expertise in both startups & large corporations. Fred holds a BS in Mech. Eng. & an MS in Eng. Management, serving on multiple medical device boards & Cornell's Biomedical Engineering Advisory Board.
Ian Clements, M.Sc., boasts 30+ years in pharmaceutical companies' sales, marketing, and business development. As COO of Santalis Healthcare & Pharmaceuticals, he co-founded Santalis. A Managing Partner at Targeted Technology Fund II, he holds degrees from Swansea University and King’s College London & has been a StemBioSys board member since 2013.
Jean Cheever, MBA, CPA, is a former finance executive with Bristol-Myers Squibb and is currently active in the Austin/San Antonio startup community. She holds an MBA from UT Austin and recently retired from the board of Broadway Bank where she served for more than 25 years. Jean has been a StemBioSys board member since 2013.
30+ years of experience in healthcare, primarily in medical devices
Paul Castella, PhD, MBA, excels in developing & commercializing life science startups. Co-founder of CardioSpectra, acquired for $63M, he's also led Xenotope Diagnostics and ViroXis. With 20 patents, he co-founded Targeted Technology Fund I in 2009. Dr. Castella serves on multiple biotech boards and has been on the StemBioSys Board since 2013.
Show 1 more personShow fewer
Robert Langer holds approximately 1500 global patents, licensed or sub-licensed to 400+ firms, & has 42 honorary doctorates including from Harvard & Yale. As MIT's esteemed David H. Koch Institute Professor, he’s won 220+ major awards, like the Draper Prize (considered the engineering Nobel prize) & is the most cited engineer in history. He has a Sc.D. from MIT and a B.S. from Cornell.
Names and titles as disclosed on StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 12 filings on EDGAR- Form C-TRApr 22, 20260001568861-26-000002EDGAR
- Form C-ARApr 10, 20250001665160-25-000583EDGAR
- Form C-USep 25, 20240001665160-24-001346EDGAR
- Form CJun 5, 20240001665160-24-000955EDGAR
- Form DDec 30, 20200001568861-20-000003EDGAR
- Form DJan 9, 20200001568861-20-000001EDGAR
- Form DJun 19, 20190001568861-19-000001EDGAR
- Form D/AMay 15, 20180001568861-18-000001EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.